S2409 PRISM: Biomarker-Driven ES-SCLC Therapy - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
Protocol S2409, PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC) (NCT# 06769126)
Principal Investigator
Laura Alder, MD
Medical Oncologist
Protocol Number
IRB:
PRO00119900
NCT:
NCT06769126
Phase
Phase II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment